Figure 2.
β1C immunoreactivity is retained in the majority of invasive duct carcinomas (A) and lobular carcinomas (B) of the breast. Down-regulation (C) or complete lack (D) of β1C expression is a feature of 40.3% of invasive carcinomas. Non-neoplastic mammary ducts provide built-in positive controls of immunostaining. Original magnifications: A and B, ×400; C, ×250; D, ×100.